Drug intelligence / Profile preview

prosetron

Development stage: Preclinical
Modality: Small Molecules

Overview

Prosetron is a pharmaceutical drug, likely a small molecule, that is presumed to function as a 5-HT3 receptor antagonist. It is being evaluated as a control treatment in a clinical trial for managing gastrointestinal reactions, specifically nausea and vomiting, caused by tumor chemotherapy. Its therapeutic effect is expected to stem from blocking the action of serotonin at the 5-HT3 receptors.

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on prosetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prosetron.

Explore the full profile